[go: up one dir, main page]

HUP9900213A1 - Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére - Google Patents

Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére

Info

Publication number
HUP9900213A1
HUP9900213A1 HU9900213A HUP9900213A HUP9900213A1 HU P9900213 A1 HUP9900213 A1 HU P9900213A1 HU 9900213 A HU9900213 A HU 9900213A HU P9900213 A HUP9900213 A HU P9900213A HU P9900213 A1 HUP9900213 A1 HU P9900213A1
Authority
HU
Hungary
Prior art keywords
gestagene
effects
compositions
pharmaceutical compositions
type
Prior art date
Application number
HU9900213A
Other languages
English (en)
Inventor
Gábor Bogye
Original Assignee
Gábor Bogye
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gábor Bogye filed Critical Gábor Bogye
Priority to HU9900213A priority Critical patent/HUP9900213A1/hu
Publication of HU9900213D0 publication Critical patent/HU9900213D0/hu
Priority to AT00903916T priority patent/ATE368464T1/de
Priority to PCT/HU2000/000009 priority patent/WO2000044385A1/en
Priority to DE60035771T priority patent/DE60035771T2/de
Priority to ES00903916T priority patent/ES2286997T3/es
Priority to DK00903916T priority patent/DK1148882T3/da
Priority to EP00903916A priority patent/EP1148882B1/en
Priority to PT00903916T priority patent/PT1148882E/pt
Priority to AU25664/00A priority patent/AU2566400A/en
Publication of HUP9900213A1 publication Critical patent/HUP9900213A1/hu
Priority to CY20071101390T priority patent/CY1106961T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgya gesztagén típusú szteroidhormon(oka)t ésplazmahomocisztein-szintet csökkentő vegyülete(ke)t tartalmazó olyangyógykompozíció(k), amely(ek) alkalmazása során mérséklődik agesztagén típusú hormont tartalmazó gyógyszer(ek) thromb-emboliásmellékhatásainak rizikója. Ó
HU9900213A 1999-02-01 1999-02-01 Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére HUP9900213A1 (hu)

Priority Applications (10)

Application Number Priority Date Filing Date Title
HU9900213A HUP9900213A1 (hu) 1999-02-01 1999-02-01 Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére
AU25664/00A AU2566400A (en) 1999-02-01 2000-01-28 Pharmaceutical combination of progesterone and folic acid
ES00903916T ES2286997T3 (es) 1999-02-01 2000-01-28 Utilizacion de un compuesto para reducir el contenido de homocistina en plasma, para la reduccion del riesgo de efectos tromboembolicos secundarios inducidos por hormonas gestagenicas.
PCT/HU2000/000009 WO2000044385A1 (en) 1999-02-01 2000-01-28 Pharmaceutical combination of progesterone and folic acid
DE60035771T DE60035771T2 (de) 1999-02-01 2000-01-28 Verwendung eines den Plasmahomocysteingehalt reduzierenden Wirkstoffs zur Verminderung des Risikos von durch Hormone vom Gestagentyp hervorgerufenen thromboembolischen Nebenwirkungen
AT00903916T ATE368464T1 (de) 1999-02-01 2000-01-28 Verwendung eines den plasma homocysteingehalt reduzierenden wirkstoffs zur verminderung des risikos der durch gestagen hormone verursachten thromboembolischen nebenwirkungen
DK00903916T DK1148882T3 (da) 1999-02-01 2000-01-28 Anvendelse af middel til reduktion af homocysteinindholdet i plasma til reduktion af risikoen for tromboembolisk bivirkning fremkaldt af hormoner af gestagentypen
EP00903916A EP1148882B1 (en) 1999-02-01 2000-01-28 Use of a plasma homocysteine content reducing agent for the reduction of the thromboembolic side effect risk induced by gestagen type hormones
PT00903916T PT1148882E (pt) 1999-02-01 2000-01-28 Utilização de um agente redutor do teor de homocisteína no plasma para redução do risco de efeitos secundários tromboembólicos induzidos por hormonas do tipo dos gestagénios
CY20071101390T CY1106961T1 (el) 1999-02-01 2007-10-29 Χρηση παραγοντα μειωσης περιεκτικοτητας ομοκυστεϊνης πλασματος για τη μειωση του κινδυνου θρομβοεμβολικης παρενεργειας που προκαλειται απο ορμονες τυπου προγεστερονης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9900213A HUP9900213A1 (hu) 1999-02-01 1999-02-01 Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére

Publications (2)

Publication Number Publication Date
HU9900213D0 HU9900213D0 (en) 1999-03-29
HUP9900213A1 true HUP9900213A1 (hu) 2000-12-28

Family

ID=89997698

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900213A HUP9900213A1 (hu) 1999-02-01 1999-02-01 Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére

Country Status (10)

Country Link
EP (1) EP1148882B1 (hu)
AT (1) ATE368464T1 (hu)
AU (1) AU2566400A (hu)
CY (1) CY1106961T1 (hu)
DE (1) DE60035771T2 (hu)
DK (1) DK1148882T3 (hu)
ES (1) ES2286997T3 (hu)
HU (1) HUP9900213A1 (hu)
PT (1) PT1148882E (hu)
WO (1) WO2000044385A1 (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3567699A (en) * 1998-04-17 1999-11-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102005053771A1 (de) 2005-11-09 2007-05-10 Grünenthal GmbH Darreichform zur hormonalen Kontrazeption

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2131292B (en) * 1982-12-01 1987-03-11 Dr Christopher H Mortimer Progestational pharmaceutical formulations
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
BE1012495A3 (fr) * 1999-03-02 2000-11-07 Messadek Jallal La glycine-betaine pour son usage antithrombotique.

Also Published As

Publication number Publication date
ES2286997T3 (es) 2007-12-16
PT1148882E (pt) 2007-11-08
ATE368464T1 (de) 2007-08-15
CY1106961T1 (el) 2012-09-26
HU9900213D0 (en) 1999-03-29
EP1148882A1 (en) 2001-10-31
WO2000044385A1 (en) 2000-08-03
DE60035771D1 (de) 2007-09-13
AU2566400A (en) 2000-08-18
EP1148882B1 (en) 2007-08-01
DE60035771T2 (de) 2008-04-30
DK1148882T3 (da) 2007-11-26

Similar Documents

Publication Publication Date Title
PL337794A1 (en) Pharmaceutic agent for oral administration containing an active substance and cyclodextrin
IL141762A0 (en) New oral formulations
EP1033981A4 (en) FORMULATIONS AND METHODS FOR REDUCING THE TOXICITY OF ANTINEOPLASTIC AGENTS
AU2513900A (en) Drug dosage unit for buccal administration of steroidal active agents
MY118151A (en) Pharmaceutical formulations containing voriconazole.
AP1954A (en) Controlled release compositions comprising nimesulide.
IL121160A0 (en) Method compositions and kits for increasing the oral bioavailability of pharmaceutical agents
NO20032511L (no) Farmasöytiske sammensetninger for oral tilförsel av farmakologisk aktive midler
AU2001260414A1 (en) Pharmaceutical compositions for transdermal administration of anti-inflammatory agents
PT1126828E (pt) Administração oral de análogos de adenosina
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
DE60031504D1 (de) Fluticasonpropionat arzneizubereitung
AU2084801A (en) Antiviral medication
GB2411116A (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
HUP0203721A2 (hu) Új hormonkészítmény és alkalmazása
PL348202A1 (en) Pharmaceutically active composition and dispensing device
HUP9900213A1 (hu) Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére
GEP20043377B (en) Pharmaceutical Complex
AU2502301A (en) Medicament and combination of compatible medicaments
WO2001032191A3 (en) Phytoestrogenic pharmaceutical preparations
IL142112A0 (en) Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues
MX2007009061A (es) Preparacion farmaceutica para la anticoncepcion oral.
WO1997049431A3 (en) Use of oligosaccharides for neutralising e. coli toxins
AU5249500A (en) Medicinal composition for oral administration

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees